{"id":"NCT00330733","sponsor":"VA Office of Research and Development","briefTitle":"Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk","officialTitle":"Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-01","primaryCompletion":"2010-08","completion":"2010-09","firstPosted":"2006-05-29","resultsPosted":"2014-04-22","lastUpdate":"2020-01-21"},"enrollment":71,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Atherosclerosis","Cardiovascular Disease","Inflammation","Insulin Resistance","Noninsulin-dependent Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Salsalate","otherNames":["Amigesic","Anaflex","Argesic-SA","Disalcid","Marthritic","Mono-Gesic","Salflex","Salsitab"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Salsalate Therapy","type":"ACTIVE_COMPARATOR"}],"summary":"The hypothesis is that salsalate therapy may be an effective and safe method to modulate inflammation in metabolically-critical tissues and thus reduce insulin resistance and its related complications.\n\nThe objectives of the study are to (1) determine whether salsalate therapy improves insulin resistance in subjects with IGT and changes in glucose area under the curve following a standard oral glucose tolerance test (OGTT); (2) determine whether salsalate therapy reduces a) plasma levels of a variety of well established inflammatory proteins and b) mononuclear cell inflammatory activity to provide evidence of reduced systemic and tissue inflammation, respectively; and (3)also determine whether salsalate therapy improves parameters of cardiovascular disease risk, including features of metabolic syndrome (fasting glucose, triglycerides, HDL, and blood pressure) as well as endothelial dysfunction.","primaryOutcome":{"measure":"Change in Systemic Glucose Disposal- Glucose Infusion Rates","timeFrame":"3 months","effectByArm":[{"arm":"Placebo","deltaMin":1,"sd":null},{"arm":"Salsalate Therapy","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23370525"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":["nausea","tinnitus"]}}